Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diabetinol
- Development stage
- Unknown
- Lead developer
- Diabetinol
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Diabetinol is a plant-based nutraceutical complex developed for the management of blood glucose and HbA1c levels in patients with type 2 diabetes mellitus. The formulation is primarily composed of citrus bioflavonoids, specifically nobiletin (49%) and tangeretin (13%), supplemented with limonoids, tocotrienols, and vitamin E. It functions as an adjunctive therapy to conventional antidiabetic medications like metformin, aiming to improve glucose tolerance and insulin sensitivity while providing cardiovascular benefits by lowering total cholesterol and LDL-C levels. Clinical data from a 24-week randomized controlled trial indicates that Diabetinol can help patients achieve glycemic and lipid targets more effectively than conventional therapy alone. Mangoceuticals (MangoRx) acquired the exclusive rights to manufacture and distribute the product in the U.S. and Canada from Navy Wharf in 2024.
- Brand names
- Diabetinol
- Other names
- citrus bioflavonoid complex
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)SLC2A4 (Solute carrier family 2 facilitated glucose transporter member 4)
Beyond the preview
Go deeper on Diabetinol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Diabetinol.